Nanog, as a key cancer stem cell marker in tumor progression.


Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
15 Jun 2022
Historique:
received: 06 11 2021
revised: 16 02 2022
accepted: 18 03 2022
pubmed: 27 3 2022
medline: 14 5 2022
entrez: 26 3 2022
Statut: ppublish

Résumé

Cancer stem cells (CSCs) are a small population of malignant cells that induce tumor onset and development. CSCs share similar features with normal stem cells in the case of self-renewal and differentiation. They also contribute to chemoresistance and metastasis of cancer cells, leading to therapeutic failure. To identify CSCs, multiple cell surface markers have been characterized, including Nanog, which is found at high levels in different cancers. Recent studies have revealed that Nanog upregulation has a substantial association with the advanced stages and poor prognosis of malignancies, playing a pivotal role through tumorigenesis of multiple human cancers, including leukemia, liver, colorectal, prostate, ovarian, lung, head and neck, brain, pancreatic, gastric and breast cancers. Nanog through different signaling pathways, like JAK/STAT and Wnt/β-catenin pathways, induces stemness, self-renewal, metastasis, invasiveness, and chemoresistance of cancer cells. Some of these signaling pathways are common in various types of cancers, but some have been found in one or two cancers. Therefore, this review aimed to focus on the function of Nanog in multiple cancers based on recent studies surveying the suitable approaches to target Nanog and inhibit CSCs residing in tumors to gain favorable results from cancer treatments.

Identifiants

pubmed: 35337852
pii: S0378-1119(22)00267-0
doi: 10.1016/j.gene.2022.146448
pii:
doi:

Substances chimiques

NANOG protein, human 0
Nanog Homeobox Protein 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

146448

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Parisa Vasefifar (P)

Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Rouhollah Motafakkerazad (R)

Department of Plant Biology, Faculty of Natural Science, University of Tabriz, Iran. Electronic address: rmotafakker@tabrizu.ac.ir.

Leili Aghebati Maleki (LA)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Souzan Najafi (S)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Farid Ghrobaninezhad (F)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Basira Najafzadeh (B)

Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

Hajar Alemohammad (H)

Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

Mohammad Amini (M)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Amir Baghbanzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH